The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Ding J, Chen X, Gao Z, et al. Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos. 2013;41:1195–1210. doi:10.1124/dmd.112.05031023509226
   PubMed Web of Science ®Google Scholar
• Miao M, Deng G, Luo S, et al. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 2018;148:286–290. doi:10.1016/j.ygyno.2017.12.01329248198
   PubMed Web of Science ®Google Scholar
• Lan CY, Wang Y, Xiong Y, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol. 2018. doi:10.1016/S1470-2045(18)30349-8
   PubMed Web of Science ®Google Scholar
• Hu X, Zhang J, Xu B, et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135:1961–1969. doi:10.1002/ijc.2882924604288
   PubMed Web of Science ®Google Scholar
• Zhang Y, Han C, Li J, et al. Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study. Sci Rep. 2017;7:13208. doi:10.1038/s41598-017-13192-829038432
   PubMed Web of Science ®Google Scholar
• Brower V. Apatinib in treatment of refractory gastric cancer. Lancet Oncol. 2016;17:e137. doi:10.1016/S1470-2045(16)00138-8
   PubMed Web of Science ®Google Scholar
• Xu J, Liu X, Yang S, Zhang X, Shi Y. Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study. Onco Targets Ther. 2017;10:4989–4995. doi:10.2147/OTT.S14268629075129
   PubMed Web of Science ®Google Scholar
• Zhen L, Jiali C, Yong F, Han X, Hongming P, Weidong H. The efficacy and safety of apatinib treatment for patients with unresectable or relapsed liver cancer: a retrospective study. J Cancer. 2018;9:2773–2777. doi:10.7150/jca.2637630123344
   PubMed Web of Science ®Google Scholar
• Qiu H, Li J, Liu Q, Tang M, Wang Y. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel. Cell Cycle. 2018;1–10.
   Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–181. doi:10.1016/S1053-4296(03)00031-612903007
   PubMed Web of Science ®Google Scholar
• Eskander RN, Tewari KS. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol. 2014;26:314–321. doi:10.1097/GCO.000000000000004224979076
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649–4655. doi:10.1200/JCO.2009.21.890919720909
   PubMed Web of Science ®Google Scholar
• Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 2005;7:419–434.16221379
   PubMedGoogle Scholar
• Hu X, Cao J, Hu W, et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14:820. doi:10.1186/1471-2407-14-82025376790
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. doi:10.1056/NEJMoa070885718650514
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134. doi:10.1056/NEJMoa06065517215530
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734–743. doi:10.1056/NEJMoa130974824552320
   PubMed Web of Science ®Google Scholar
• Farley J, Sill MW, Birrer M, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;121:303–308. doi:10.1016/j.ygyno.2011.01.03021329967
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009;27:1069–1074. doi:10.1200/JCO.2008.18.904319139430
   PubMed Web of Science ®Google Scholar
• Bizzarri N, Ghirardi V, Alessandri F, et al. Bevacizumab for the treatment of cervical cancer. Expert Opin Biol Ther. 2016;16:407–419. doi:10.1517/14712598.2016.114520826796332
   PubMed Web of Science ®Google Scholar
• Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG trial IND.184. Gynecol Oncol. 2010;116:163–167. doi:10.1016/j.ygyno.2009.08.01219740535
   PubMed Web of Science ®Google Scholar
• Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64:3731–3736. doi:10.1158/0008-5472.CAN-04-007415172975
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10:417–427. doi:10.1038/nrd345521629292
   PubMed Web of Science ®Google Scholar
• Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013;11:172–191. doi:10.1016/j.ejcsup.2013.07.01626217127
   PubMedGoogle Scholar